Display options
Cite
Oikonomou E, Paraskevas T, Velissaris D. Cardiac biomarkers alterations in patients with SARS-CoV-2 infection. Rom J Intern Med. 2021;doi: 10.2478/rjim-2021-0037.
Oikonomou, E., Paraskevas, T., & Velissaris, D. (2021). Cardiac biomarkers alterations in patients with SARS-CoV-2 infection. Romanian journal of internal medicine = Revue roumaine de medecine interne, . https://doi.org/10.2478/rjim-2021-0037
Oikonomou, Eleousa, et al. "Cardiac biomarkers alterations in patients with SARS-CoV-2 infection." Romanian journal of internal medicine = Revue roumaine de medecine interne vol. (2021). doi: https://doi.org/10.2478/rjim-2021-0037
Oikonomou E, Paraskevas T, Velissaris D. Cardiac biomarkers alterations in patients with SARS-CoV-2 infection. Rom J Intern Med. 2021 Oct 05; doi: 10.2478/rjim-2021-0037. Epub 2021 Oct 05. PMID: 34610232.
Copy Download .nbib Format: NLM
Share it on

Rom J Intern Med. 2021 Oct 05; doi: 10.2478/rjim-2021-0037. Epub 2021 Oct 05.

Cardiac biomarkers alterations in patients with SARS-CoV-2 infection.

Romanian journal of internal medicine = Revue roumaine de medecine interne

Eleousa Oikonomou, Themistoklis Paraskevas, Dimitrios Velissaris

Affiliations

  1. Department of Internal Medicine, University Hospital of Patras, Greece.

PMID: 34610232 DOI: 10.2478/rjim-2021-0037

Abstract

Reliable biomarkers are necessary for the risk stratification of patients infected with SARS-CoV-2. This novel coronavirus is now established to affect several organs in addition to the lungs, most prominently the heart. This is achieved through direct damage to the myocardium and indirect immune-associated effects during the cytokine storm. We performed a literature review aiming to identify the prognostic value of alterations of cardiac biomarkers in SARS-CoV-2 infection. Cardiac biomarkers are significantly elevated in patients with severe COVID-19 and are independent predictors of mortality. High-sensitivity troponin I and T are correlated with multiple inflammatory indexes and poor outcomes. Although cut-off values have been established for most of cardiac biomarkers, lower limits for troponins may have better prognostic values and longitudinal monitoring of cardiac biomarkers can help the clinician assess the patient's course. Additional measurements of NT-proBNP, can detect the subgroup of patients with poor prognosis.

© 2021 Eleousa Oikonomou et al., published by Sciendo.

Keywords: SARS-CoV-2; biomarkers; natriuritic peptides; prognosis; troponins

References

  1. 1. KURZ DJ, EBERLI FR. Cardiovascular aspects of COVID-19. Swiss Med Wkly. 2020;150:w20417. - PubMed
  2. 2. BHALLA V, BLISH CA, SOUTH AM. A historical perspective on ACE2 in the COVID-19 era [published online ahead of print, 2020 Dec 14]. J Hum Hypertens. 2020;1-5. - PubMed
  3. 3. BADER F, MANLA Y, ATALLAH B, STARLING RC. Heart failure and COVID-19. Heart Fail Rev. 2021;26(1):1-10. - PubMed
  4. 4. IMAZIO M, KLINGEL K, KINDERMANN I, BRUCATO A, DE ROSA FG, ADLER Y, et al. COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?. Heart. 2020;106(15):1127-1131. - PubMed
  5. 5. LI L, ZHOU Q, XU J. Changes of Laboratory Cardiac Markers and Mechanisms of Cardiac Injury in Coronavirus Disease 2019. Biomed Res Int. 2020;2020:7413673. - PubMed
  6. 6. ABOUGHDIR M, KIRWIN T, ABDUL KHADER A, WANG B. Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review. Viruses. 2020;12(5):527. - PubMed
  7. 7. SHI X, CHEN M, ZHANG Y. The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19. Mol Biol Rep. 2021;48(2):1763-1771. - PubMed
  8. 8. WU L, O’KANE AM, PENG H, BI Y, MOTRIUK-SMITH D, REN J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochem Pharmacol. 2020;178:114114. - PubMed
  9. 9. ADEGHATE EA, EID N, SINGH J. Mechanisms of COVID-19-induced heart failure: a short review. Heart Fail Rev. 2021;26(2):363-369. - PubMed
  10. 10. COSTA IBSDS, BITTAR CS, RIZK SI, ARAÚJO FILHO AE, SANTOS KAQ, MACHADO TIV, et al. The Heart and COVID-19: What Cardiologists Need to Know. O Coração e a COVID-19: O que o Cardiologista Precisa Saber. Arq Bras Cardiol. 2020;114(5):805-816. - PubMed
  11. 11. HUANG C, WANG Y, LI X, REN L, ZHAO J, HU Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. - PubMed
  12. 12. MALIK P, PATEL U, PATEL NH, SOMI S, SINGH J. Elevated cardiac troponin I as a predictor of outcomes in COVID-19 hospitalizations: a meta-analysis. Infez Med. 2020;28(4):500-506. - PubMed
  13. 13. BAGATE F, MASI P, D’HUMIÈRES T, AL-ASSAAD L, CHAKRA LA, RAZAZI K, et al. Advanced echocardiographic phenotyping of critically ill patients with coronavirus-19 sepsis: a prospective cohort study. J Intensive Care. 2021;9(1):12. - PubMed
  14. 14. LI X, PAN X, LI Y, AN N, XING Y, YANG F, et al. Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review. Crit Care. 2020;24(1):468. - PubMed
  15. 15. GIUSTINO G, CROFT LB, STEFANINI GG, BRAGATO R, SILBIGER JJ, VICENZI M, et al. Characterization of Myocardial Injury in Patients With COVID-19. J Am Coll Cardiol. 2020;76(18):2043-2055. - PubMed
  16. 16. PEIRÓ ÓM, CARRASQUER A, SÁNCHEZ-GIMENEZ R, LAL-TREHAN N, DEL-MORAL-RONDA V, BONET G, et al. Biomarkers and short-term prognosis in COVID-19. Biomarkers. 2021;26(2):119-126. - PubMed
  17. 17. SHOAR S, HOSSEINI F, NADERAN M, MEHTA JL. Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors Versus Non-survivors in Patients With COVID-19. Am J Cardiol. 2020;135:50-61. - PubMed
  18. 18. LI J, ZHANG Y, WANG F, LIU B, LI H, TANG Z, et al. Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19). BMC Cardiovasc Disord. 2020;20(1):479. - PubMed
  19. 19. MU S, WEI W, JIN C, PU N, YU K, GU G, et al. Risk factors for COVID-19 patients with cardiac injury: pulmonary ventilation dysfunction and oxygen inhalation insufficiency are not the direct causes. Aging (Albany NY). 2020;12(23):23464-23477. - PubMed
  20. 20. SHAH P, DOSHI R, CHENNA A, OWENS R, COBB A, IVEY H, et al. Prognostic Value of Elevated Cardiac Troponin I in Hospitalized Covid-19 Patients. Am J Cardiol. 2020;135:150-153. - PubMed
  21. 21. ÖZYILMAZ S, ERGÜN ALIŞ E, ERMIŞ E, ALLAHVERDIYEV S, UÇAR H. Assessment of the Relationship between Mortality and Troponin I Levels in Hospitalized Patients with the Novel Coronavirus (COVID-19). Medicina (Kaunas). 2020;56(12):693. - PubMed
  22. 22. MEDETALIBEYOGLU A, EMET S, SENKAL N, AYDOGAN M, KOSE M, TUKEK T. Cardiovascular view of intermediate and high-risk COVID-19 patients: single-centre experience with low mortality and intensive care hospitalisation rates. Cardiovasc J Afr. 2021;32(2):79-86. - PubMed
  23. 23. ARCARI L, LUCIANI M, CACCIOTTI L, MUSUMECI MB, SPUNTARELLI V, PISTELLA E, et al. Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. Intern Emerg Med. 2020;15(8):1467-1476. - PubMed
  24. 24. STEFANINI GG, CHIARITO M, FERRANTE G, CANNATA F, AZZOLINI E, VIGGIANI G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106(19):1512-1518. - PubMed
  25. 25. QIN JJ, CHENG X, ZHOU F, LEI F, AKOLKAR G, CAI J, et al. Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. Hypertension. 2020;76(4):1104-1112. - PubMed
  26. 26. SALVATICI M, BARBIERI B, CIOFFI SMG, MORENGHI E, LEONE FP, MAURA F, et al. Association between cardiac troponin I and mortality in patients with COVID-19. Biomarkers. 2020;25(8):634-640 - PubMed
  27. 27. CAO J, ZHENG Y, LUO Z, MEI Z, YAO Y, LIU Z, et al. Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease. Theranostics. 2020;10(21):9663-9673. - PubMed
  28. 28. HODGES G, PALLISGAARD J, SCHJERNING OLSEN AM, MCGETTIGAN P, ANDERSEN M, KROGAGER M, et al. Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study. BMJ Open. 2020;10(12):e041295. - PubMed
  29. 29. RAAD M, DABBAGH M, GORGIS S, YAN J, CHEHAB O, DAGHER C, et al. Cardiac Injury Patterns and Inpatient Outcomes Among Patients Admitted With COVID-19. Am J Cardiol. 2020;133:154-161. - PubMed
  30. 30. TORAIH EA, ELSHAZLI RM, HUSSEIN MH, ELGAML A, AMIN M, EL-MOWAFY M, et al. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis. J Med Virol. 2020;92(11):2473-2488. - PubMed
  31. 31. HE X, WANG L, WANG H, XIE Y, YU Y, SUN J, et al. Factors associated with acute cardiac injury and their effects on mortality in patients with COVID-19. Sci Rep. 2020;10(1):20452. - PubMed
  32. 32. YAO Q, NI J, HU TT, CAI ZL, ZHAO JH, XIE QW, et al. Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study. Rev Cardiovasc Med. 2020;21(4):615-625. - PubMed
  33. 33. ALOISIO E, CHIBIREVA M, SERAFINI L, PASQUALETTI S, FALVELLA FS, DOLCI A, et al. A Comprehensive Appraisal of Laboratory Biochemistry Tests as Major Predictors of COVID-19 Severity. Arch Pathol Lab Med. 2020;144(12):1457-1464. - PubMed
  34. 34. SINGH N, ANCHAN RK, BESSER SA, BELKIN MN, CRUZ MD, LEE L, et al. High sensitivity Troponin-T for prediction of adverse events in patients with COVID-19. Biomarkers. 2020;25(8):626-633. - PubMed
  35. 35. LI C, JIANG J, WANG F, ZHOU N, VERONESE G, MOSLEHI JJ, et al. Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients. J Mol Cell Cardiol. 2020;147:74-87. - PubMed
  36. 36. POTERUCHA TJ, ELIAS P, JAIN SS, SAYER G, REDFORS B, BURKHOFF D, et al. Admission Cardiac Diagnostic Testing with Electrocardiography and Troponin Measurement Prognosticates Increased 30-Day Mortality in COVID-19. J Am Heart Assoc. 2021;10(1):e018476. - PubMed
  37. 37. SI D, DU B, NI L, YANG B, SUN H, JIANG N, et al. Death, discharge and arrhythmias among patients with COVID-19 and cardiac injury. CMAJ. 2020;192(28):E791-E798. - PubMed
  38. 38. ZHOU M, WONG CK, UN KC, LAU YM, LEE JC, TAM FC et al. Cardiovascular sequalae in uncomplicated COVID-19 survivors. PLoS One. 2021;16(2):e0246732. - PubMed
  39. 39. GHIO S, BALDI E, VICENTINI A, LENTI MV, DI SABATINO A, DI MATTEO A, et al. Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. Intern Emerg Med. 2020;15(8):1457-1465. - PubMed
  40. 40. LI J, GUO T, DONG D, ZHANG X, CHEN X, FENG Y, et al. Defining heart disease risk for death in COVID-19 infection. QJM. 2020;113(12):876-882. - PubMed
  41. 41. BELARTE-TORNERO LC, VALDIVIELSO-MORÉ S, VICENTE ELCANO M, SOLÉ-GONZÁLEZ E, RUÍZ-BUSTILLO S, CALVO-FERNÁNDEZ A, et al. Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection. J Clin Med. 2021;10(2):323. - PubMed
  42. 42. ZYLLA MM, MERLE U, VEY JA, KOROSOGLOU G, HOFMANN E, MÜLLER M, et al. Predictors and Prognostic Implications of Cardiac Arrhythmias in Patients Hospitalized for COVID-19. J Clin Med. 2021;10(1):133. - PubMed
  43. 43. MANOCHA KK, KIRZNER J, YING X, YEO I, PELTZER B, ANG B, et al. Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized With COVID-19: Derivation and Validation of the HA2T2 COVID-19 Mortality Risk Score. J Am Heart Assoc. 2021;10(6):e018477. - PubMed
  44. 44. MAHMOUD-ELSAYED HM, MOODY WE, BRADLOW WM, KHAN-KHEIL AM, SENIOR J, HUDSMITH LE, et al. Echocardiographic Findings in Patients With COVID-19 Pneumonia. Can J Cardiol. 2020;36(8):1203-1207. - PubMed
  45. 45. CHEN LQ, BURDOWSKI J, MARFATIA R, WEBER J, GLIGANIC K, DIAZ N, et al. Reduced cardiac function is associated with cardiac injury and mortality risk in hospitalized COVID-19 Patients. Clin Cardiol. 2020;43(12):1547-1554. - PubMed
  46. 46. VAN DEN HEUVEL FMA, VOS JL, KOOP Y, VAN DIJK APJ, DUIJNHOUWER AL, DE MAST Q, et al. Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19. Neth Heart J. 2020;28(7-8):410-417. - PubMed
  47. 47. LAZZERI C, BONIZZOLI M, BATACCHI S, CIANCHI G, FRANCI A, FULCERI GE, et al. Cardiac Involvment in COVID-19-Related Acute Respiratory Distress Syndrome. Am J Cardiol. 2020;132:147-149. - PubMed
  48. 48. GHIO S, BALDI E, VICENTINI A, LENTI MV, DI SABATINO A, DI MATTEO A, et al. Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. Intern Emerg Med. 2020;15(8):1457-1465. - PubMed
  49. 49. SONSOZ MR, ONCUL A, CEVIK E, ORTA H, YILMAZ M, AYDUK GOVDELI E, et al. Wide QRS Complex and Lateral ST-T Segment Abnormality Are Associated With Worse Clinical Outcomes in COVID-19 Patients. Am J Med Sci. 2021;361(5):591-597. - PubMed
  50. 50. SANGHVI SK, SCHWARZMAN LS, NAZIR NT. Cardiac MRI and Myocardial Injury in COVID-19: Diagnosis, Risk Stratification and Prognosis. Diagnostics (Basel). 2021;11(1):130. - PubMed
  51. 51. KNIGHT DS, KOTECHA T, RAZVI Y, CHACKO L, BROWN JT, JEETLEY PS, et al. COVID-19: Myocardial Injury in Survivors. Circulation. 2020;142(11):1120-1122. - PubMed
  52. 52. LAI CC, SUNG MI, HO CH, LIU HH, CHEN CM, CHIANG SR, et al. The prognostic value of N-terminal proB-type natriuretic peptide in patients with acute respiratory distress syndrome. Sci Rep. 2017;7:44784. - PubMed
  53. 53. UELAND T, HEGGELUND L, LIND A, HOLTEN AR, TONBY K, MICHELSEN AE, et al. Elevated plasma sTIM-3 levels in patients with severe COVID-19. J Allergy Clin Immunol. 2021;147(1):92-98. - PubMed
  54. 54. BANSAL A, KUMAR A, PATEL D, PURI R, KALRA A, KAPADIA SR, et al. Meta-analysis Comparing Outcomes in Patients With and Without Cardiac Injury and Coronavirus Disease 2019 (COVID 19). Am J Cardiol. 2021;141:140-146. - PubMed
  55. 55. PRANATA R, HUANG I, LUKITO AA, RAHARJO SB. Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis. Postgrad Med J. 2020;96(1137):387-391. - PubMed
  56. 56. GAO L, JIANG D, WEN XS, CHENG XC, SUN M, HE B, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):83. - PubMed
  57. 57. ABDEEN Y, KAAKO A, ALNABULSI M, OKEH A, MENG W, MILLER R. The prognostic effect of brain natriuretic peptide levels on outcomes of hospitalized patients with COVID-19. Avicenna J Med. 2021;11(1):20-26. - PubMed
  58. 58. ALMEIDA JUNIOR GLG, BRAGA F, JORGE JK, NOBRE GF, KALICHSZTEIN M, FARIA PMP, et al. Prognostic Value of Troponin-T and B-Type Natriuretic Peptide in Patients Hospitalized for COVID-19. Valor Prognóstico da Troponina T e do Peptídeo Natriurético Tipo B em Pacientes Internados por COVID-19. Arq Bras Cardiol. 2020;115(4):660-666. - PubMed
  59. 59. MYHRE PL, PREBENSEN C, STRAND H, RØYSLAND R, JONASSEN CM, RANGBERG A, et al. Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19. Circulation. 2020;142(22):2128-2137. - PubMed

Publication Types